UPDATE: Jefferies Initiates NewLink Genetics at Buy on Immunotherapy Platform Upside

In a report published Friday, Jefferies analyst Biren Amin initiated coverage on NewLink Genetics (NASDAQ: NLNK ) with a Buy rating and $29.00 price target. In the report, Jefferies noted, “We believe multiple data readouts with potentially positive outcomes over the next 12-18 months offer attractive upside to NLNK shares. Final